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New insights of Raman spectroscopy for oral clinical applications 
Luis Felipe das Chagas e Silva de Carvalhoa,c,d,e and Marcelo Saito Nogueirab,d,e 
Oral injuries are currently diagnosed by histopathological analysis of biopsy, which is an invasive procedure and does not 
give immediate results. On the other hand, Raman spectroscopy technique is a real-time and minimally invasive analytical 
tool, with notable diagnostic capability. At the current stage, researchers are widely aware of the diagnostic potential of the 
technique and how it is considered promising for providing biochemical information  in real-time and without damaging the 
tissue. The problem originates from the lack of relevant studies and clinical trials that could show the actual use of Raman 
spectroscopy to help patients. Our goal here is to narrow the relationship between physicists, chemists, engineers, computer 
scientists, and the medical community, and in fact discurss the potential of Raman spectroscopy as a novel clinical analysis 
method. In the present study, we focused in the use of Raman spectroscopy as a daily clinical practice. In this context, 
additional studies and in vivo tests should be performed with the same approach of  a real application. We want to show to 
the scientific and industrial community what is really necessary for this, starting from a clinical point of view. Using our 
previous experience publishing in different oral pathologies and types of samples, we also aim to discuss about the current 
state, potential, and what is required to implement Raman spectroscopy for oral clinical applications. 
 
Introduction 
Many researchers have conducted studies to introduce Raman 
spectroscopy as new approaches for clinicians. However, very little 
has strong potential to help patients. At this stage, the specific point 
is how many capabilities we could use in our daily clinic. First, we 
need to share the applications for different purposes. As an example, 
a cell culture study which reports the difference between nucleus 
and cytoplasm are very important to show the big potential of the 
technique, but it does not have any clinical applications in terms of 
in vivo diagnostics or surgical guidance. Even though the technique 
(Raman spectroscopy) is the same, we have showed that if the 
instrument, probe, samples, etc is different, the final spectrum is 
totally different and cannot be related without taking into 
consideration optical properties of biological tissues1-6. 
In this way, we should primarily target diverse clinical 
applications. This includes on-site clinical applications and surgical 
guidance, involving the use of in vivo portable Raman systems or 
rapid assessment of ex vivo samples in the Hospital, very similar to 
evaluation of a frozen biopsy. Second, aiding the pathologists in their 
laboratories, it would be possible to use a Micro-Raman system for 
cell cultures or histological samples to obtain molecular information, 
which cannot be assessed by using standard histological analysis. 
Those information is extremely valuable and important to be 
publicized to clinicians so that they could contribute by improving the 
ideas about what patients really need. Obviously, many initial studies 
were performed by physicians without the presence and opinions of 
clinicians because they are really preliminary. However, at the 
current stage, we consider many of these studies not suitable for 
clinical translation, as, from our clinical experience, their published 
results will never be applied in the clinic. This occurs due to the 
simple fact that these studies do not have any applicability. 
Also, two important professionals should be supported in this 
whole process, apart from clinicians, physicians and chemists: 
biomedical engineers and computer scientists. We should 
incorporate these professionals in the team in order to give research 
groups a chance to interact with medical device companies that build 
Raman systems and to develop customized instruments for clinical 
applications. Computer scientists and related professionals are 
required in order to create and adapt scripts (in MATLAB or other 
software) for control, automation, generation of user-friendly 
interfaces, fast data acquisition and processing to help patients in 
terms of diagnostic and treatment monitoring. 
This paper aims to discuss about the current state, potential, and 
what is required to implement Raman spectroscopy for oral clinical 
applications. 
 
Oral diseases and optical biopsy 
Oral health has a strong impact in the systemic health and quality 
of life. It is defined as a “state of being free from mouth and facial 
pain, oral and throat cancer, oral infection and sores, periodontal 
(gum) disease, tooth decay, tooth loss, and other diseases and 
a. Departamento de Odontologia, Universidade de Taubaté - Brazil 
b. Tyndall National Institute, University College Cork, Lee Maltings Complex 
Dyke Parade, Cork, Postcode: T12R5CP 
c. Centro Universitário Braz Cubas - Brazil 
d. Corresponding authors: luisfelipecarvalho@hotmail.com and 
marcelosaitonogueira@gmail.com  
e. Co-first authors with equal contribution 






























































































































2 | Analyst, 2016, 00, 1-3 This journal is © The Royal Society of Chemistry 2016 
 
 
disorders that limit an individual’s capacity in biting, chewing, 
smiling, speaking, and psychosocial wellbeing” 1 by the World Health 
Organization (WHO). WHO has promoted health improvements and 
oral disease prevention by building an oral health database 2 through 
the "WHO Oral Health Country/Area Profile Programme" in the 
Country/Area Profile Project CAPP and by implementing the 
directions of the Global Oral Health Programme 3,4  
 Global initiatives allowed the development of preventive 
dentistry. In preventive dentistry, important initiatives for 
implementation of oral health programmes and integrated 
interventions were discussed in the last 11th International 
Association for Dental Research (IADR) World Congress on 
Preventive Dentistry5. Among the oral health topics, the prevention 
of oral disorders and conditions such as dental cavities (60–90% of 
school children and nearly 100% of adults have dental cavities 
worldwide), periodontal disease (severe cases found in 15–20% of 
middle-aged (35-44 years) adults), tooth loss (globally, about 30% of 
people aged 65–74 have no natural teeth), oral cancer (incidence 
ranges from one to 10 cases per 100 000 people in most countries), 
fungal, bacterial or viral infections in HIV, oro-dental trauma, noma, 
and cleft lip and palate are highlighted 1. 
 In order to prevent oral disorders, many programmes have 
focused on optical technologies, which can provide a fast, non-
invasive, molecular-sensitive, and in situ analysis of biological tissues. 
Optical techniques have the potential to be integrated in 
medical/dentist tools and can be relatively low cost compared 
techniques such as magnetic resonance imaging. These techniques 
are widely exploited in pre-clinical and clinical studies to evaluate the 
potential for implementation of an “optical biopsy” 6–23 or “spectral 
cytopathology”24. These latter concepts refer to the use of optical 
technologies as tools for clinical diagnostics, having a strong 
association with the current gold standard for disease diagnosis: the 
biopsy followed by histopathology analysis. In a conventional clinical 
setting, patients need to wait for a clinical-laboratory diagnosis, 
which may be time-consuming. This includes a set of examinations 
including biopsies and biofluid analysis. The waiting time can be 
extremely dangerous for certain oral injuries, since most of them are 
diagnosed in a later stage. This makes the treatment of oral diseases 
more expensive and difficult, compromise patients’ prognosis, and, 
consequently, increases the demand for doctors and dentists 
attention. With this in mind, optical biopsies and biofluid analyses 




Two of the most powerful optical techniques are Raman 
spectroscopy and imaging (or mapping). They have the advantage of 
being extremely molecular specific, since the captured signal has 
features of molecular bonds. Both optical techniques rely on the 
collection of Raman scattered photons, i.e., photons that undergo 
inelastic scattering through energy exchange with vibrational or 
rotational modes of molecular bonds25. Many studies in ex vivo and 
in vivo biological tissues have reported the success of the proof-of-
concept for the use of Raman spectroscopy and imaging for 
identification of oral diseases such as cancer or inflammatory 
diseases26 . In addition, in vitro studies report changes in a subcellular 
and cellular level, which can be associated with what is observed in 
a clinical study24. However, the biological variability is a factor that 
must be considered and are not consistently monitored. 
Advancements in instrument probe designs and automated analysis 
are still under development 25,27,28. 
Within this context, Raman spectroscopy can be applied in many 
areas, such as the diagnosis of early and difficult diseases, but there 
is a need for the communication between basic science (physicists, 
chemists, engineers and others) and applied science (doctors, 
dentists, among others) so that researches have a higher usability 
and are not lost with time. For example, an in vivo Raman system will 
be used clinically when we need a fast real-time response, and an 
imaged micro-Raman system may assist the pathologist in a 
laboratory for more elaborate analyses that are difficult to perform. 
The pathologist often needs complementary information from 
immunohistochemical techniques and immunofluorescence, since 
histology alone is not enough. 
Many clinicians are not aware of Raman spectroscopy, nor of its 
diagnostic ability. This hinders the progression of Raman 
spectroscopy in the clinical environment. The importance of 
presenting research in medical conferences, and scientific journals 
with medical applications is certainly a viable alternative to increase 
clinicians participating in Raman spectroscopy projects. 
Raman spectroscopy and imaging have been used for in vitro cell 
studies with two main approaches: identifying cancer cells (Raman 
microscopy or microspectroscopy) and investigation of subcellular 
processes and/or microenvironment. The first one was successful for 
differentiating a variety of cell types including neoplastic or normal 
hematopoietic cells29, leukemia cells among other types blood 
cells30, and among oral normal, dysplastic epithelial cells, and oral 
epithelial cancer 24. These differences result mostly from analysis of 
nucleic acids, lipids, carbohydrates, and protein components (such as 
amide I).  
Studies of subcellular processes are focused in the discovery of 
cellular origins of diseases that can be probed with Raman 
spectroscopy. Once these origins are clarified, choosing specific 
diseases to probe using Raman spectroscopy and evaluating its 
potential for diagnostics becomes easier. One example is the 
composition of lipid droplets in cell cytoplasm, which is related to 
atherosclerosis and Hepatitis C infection31–33. Cellular 
microenvironment has been studied by using surface enhanced 
Raman spectroscopy (SERS) to monitor pH and enzymatic activity in 
cells 34–38. Although SERS studies present a very advantageous 
concept, we have observed in recent years that its application has 
become increasingly distant from clinical practice, due to the 
instability of the signal found, difficult manipulation and 
reproducibility. 
 Previously reported studies involving ex vivo tissues are 
separated in two main approaches: complementary tool for 
histopathological analysis and alternative analysis of freshly excised 
tissues. The first approach aims to help pathologists by providing a 
chemical analysis after processing and staining the specimen. One 
alternative is reported by Lutz et. al., who demonstrated a similar 
performance between SERS immunostaining and conventional 
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fluorescent immunostaining techniques 39. The second approach is 
focused in the identification and quantification of chemical 
differences in freshly excised tissues. This is a powerful method in 
terms of reducing the time required to process the sample, since 
Raman spectroscopy and/or imaging can provide an immediate 
biochemical analysis of the specimen. However, differences in 
methodology such as time between the tissue removal and data 
collection, time when the blood supply is restricted, ambient 
conditions (such as ambient light, temperature, and humidity), and 
probe contact pressure hinder the possibility of collecting 
reproducible and reliable data. Ex vivo studies using this approach 
include the differentiation between benign and cancerous lesions in 
breast tissue 40, identification of parathyroid adenomas and 
hyperplasia in parathyroid tissue41, and estimation of higher lipid, 
protein, collagen, nucleic acid, and glycogen content in normal and 
cancerous bladder tissues42. By using Coherent anti-Stokes Raman 
scattering (CARS), a good correlation between H&E staining and 
CARS imaging was reported in ex vivo mouse brain tissue43, tissue 
morphological changes could be monitored in endothelial and 
smooth muscle cells of carotid artery (collagen fibrils and elastin) 44, 
spinal tissues and mouse sciatic nerves (demyelination and myelin 
repair processes in myelin sheaths)45. 
 
Oral clinical applications of Raman spectroscopy 
Recent oral clinical applications of Raman spectroscopy can be 
divided into disease detection46,47, determination of surgical 
margins48, and estimation of treatment response47,49–51. Disease 
detection includes studies using point measurements52–54, Raman 
microscopy55–58, and Raman mapping59–63. Raman microscopy can 
give access to biomolecular and cellular information in the same 
image, which may be useful to understand pathological processes 
involved in the studied diseases. On the other hand, Raman 
microscopy may be difficult to be translated to the clinic. The 
advantage of Raman mapping is the spatial resolution that allows 
border identification and image features extraction. However, most 
of reported studies use point measurements in order to obtain better 
spectral quality in shorter times. Disease detection applications are 
also dependent on the sample that is being probed and will be better 
discussed in the next section. Assessment of surgical margins can be 
performed by both point measurements52 and Raman imaging61,64,65. 
Imaging is more suitable for this particular application and can be 
better adapted to display the surgical margins for precise lesion 
removal. However, the implementation of this application includes 
the development of sophisticated apparatus to provide real-time and 
user-friendly information to guide the surgeon. Therefore, this 
implementation may be challenging to be done at low cost, especially 
when the existing technology available in the market is taken into 
consideration. Finally, few studies report treatment response 
prediction, including oral cancer cell monitoring66, serum analysis67, 
and in vivo68. In this case, studies in ex vivo and in vivo tissues are still 
required for the next step for proof of concept of Raman 
spectroscopy for treatment response monitoring. 
 
Samples for oral disease detection 
 Oral clinical measurements of Raman spectroscopy can be 
performed in biofluids, exfoliated cell samples, and ex vivo and in vivo 
tissues. 
Biofluid analysis has the potential to enable low-cost and 
distance diagnosis49, but its implementation in the clinic is still 
challenging and may take longer than other approaches. This 
implementation require standardizing operational (e.g. when the 
sample is analysed in the clinic workflow), sample collection (e.g. 
fasting or not fasting), and sample handling (e.g. sample volume, 
dilutions, and storage) procedures. Taking into account biological 
variability and patient behaviour aspects (e.g. smoking and 
hydration) is necessary once the first standardization takes place. 
Successful studies of biofluids for oral applications were mostly 
performed in blood69,70 (especially serum67,71–74), saliva75–78, and 
urine79. However, even though previous studies report the proof of 
concept works, further investigation is essential to move forward to 
large-scale clinical settings. 
 Analysis of exfoliated oral cells has potential to be suitable for 
screening and routine clinical applications. On the other hand, 
clinical translation is dependent on the same standardization 
procedures discussed for biofluids. In addition, the use of 
microscopes in the clinic is not common, which means the 
microscopy market needs further development in order to meet 
clinicians’ requirements before exfoliated cell applications take 
place. These applications are based on the assumption slight 
biochemical changes towards the diseased condition can be 
identified earlier than morphological alterations. Therefore, the 
sensitivity provided by Raman spectroscopy could be used to 
enhance diseased tissue features and diagnose the disease in an 
early stage. As enhanced features are mostly known by molecular 
biologists and pathologists, the supervision of these professionals is 
critical for the success of multicentre exfoliated cell studies and 
clinical translation. Research groups have reported advances in 
spectral differential analysis for normal, dysplastic, and squamous 
cell carcinoma cells56, and feasibility of spectral acquisition and cell 
collection80,81. 
 Ex vivo studies are easier and quicker to be conducted for 
validation purposes, as clinical research ethics approval takes shorter 
for non-interventional studies. Then, more multicentre studies can 
be carried out and clinical translation may happen earlier than other 
applications. Conversely, the ex vivo tissues do not reproduce the 
same conditions of in vivo tissues and the detection of slight 
biochemical changes may be more difficult. This may hinder early-
stage disease diagnosis. Also, biological variability and handling and 
storage differences among health institutions must be taken into 
consideration when analysing ex vivo tissues spectra. Reported 
studies show results for both frozen and fixed tissues to differentiate 
normal, inflammatory, precancerous, and cancerous tissues 26,46,58,82–
86. Good sensitivity and specificity was reported by Girish et. al. for 
tissue sections on Ag-TiO2 nanostructured SERS substrate 49,87. 
Initiatives to optimize the data analysis were performed by our 
group, which evaluate the classification accuracy by multivariate 
analysis methods6,7. 
 In vivo studies represent the most advantageous approach for 
clinical translation. By assessing the variation of the biochemical 
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content in early stage diseases in vivo, slight differences can be 
observed directly in the patient. Therefore, applications in the clinical 
routine are more realistic and translation is more feasible. Previous 
studies report efforts to decrease the time of spectral acquisition47,88, 
age-related and tobacco-related86 or oral anatomical subsite 
variations 89–91, and feasibility of detecting changes associated to 
cancer, precancer, and tissue malignancy92–97. The next step requires 
real-time analysis improvements in the spectra collection, signal and 
data processing, and data analysis. These improvements can 
enhance the data quality, automated system responses, and 
generation of user-friendly reports.  
 
Interference due to optical processes and implications in signal 
processing 
 Currently, there is no technique capable of measuring only 
Raman scattered photons in biological tissues. In Raman 
spectroscopy, several optical processes contribute to the captured 
signal such as fluorescence, Mie and Rayleigh scattering. Mie and 
Rayleigh scattering can lead to biased changes in the captured signal, 
since higher energy photons scatter more than the lower energy 
ones, e.g., blue light scatters more than red light. This affects both 
incident and collected light, thus making the efficiency of the 
collected signal depend on the probe geometry (such as positions of 
light source and detector and area of the detector) and the measured 
tissue profile. Tissue structures such as striations in collagen fibres 
and mitochondria membranes increase Rayleigh scattering 
scattering processes, while organelles and cell surfaces contribute to 
Mie scattering. This happens because Rayleigh and Mie scattering 
are generated by refractive index mismatches in structures smaller 
or larger than the light wavelength. On the other hand fluorescence 
occurs due to light absorption and subsequent emission of lower 
energy light by specific biomolecules, as molecules lose energy 
through vibration before emission. The observed effect in Raman 
spectra is a broad spectral background present only in biological 
tissue measurements. 
Scattering and fluorescence processes happen together in 
biological tissues, which hinders the extraction of pure Raman 
intensity spectra out of intensity measurements. In order to perform 
this extraction, the research community has used a number of 
background subtraction algorithms98,99 based on scattering 
correction and polynomial subtraction. However, subtraction of 
arbitrary baselines will not recover the ideal spectrum constituted 
only by the intensity of Raman photons, since the minimum of the 
real Raman spectrum may be different than the spectrum after the 
subtraction of a polynomial (arbitrary baseline), for example. 
Therefore, prior knowledge about the processes that contribute to 
the signal background is required in order to recover the true Raman 
spectrum. 
 In order to take optical processes contributing to the intensity of 
the underlying background in tissue Raman spectra, it is possible to 
use multimodal optical spectroscopy. By using reflectance and 
fluorescence spectroscopy, it is possible to extract fluorescence, 
absorption and scattering coefficients of biological tissues. This 
information can be coupled to Raman systems and taken into 
account when subtracting the signal background. In this case, clinical 
translation would occur only after processing algorithms for 
measurements with the three optical techniques could be 
implemented together to give a real-time analysis of the captured 
Raman signal. This implementation requires computer science 
experts in programming, integration, and automation. Another 
requirement for heterogeneous tissues is collecting the three types 
of spectra from the same spot, which may be challenging in the 
instrumentation aspect, as it involves integrating the three 
techniques in the same measurement probe. The same applies to 
analysis of ex vivo samples in a substrate, since the substrate 
spectrum should be removed by digital dewaxing100. 
  
Instrumentation standards and limitations 
 Conventional instrumentation for clinical Raman spectroscopy 
comprises a laser, fibre optic probe, spectrograph, and detector (CCD 
or spectrometer). Lasers are used to produce light in a specific, 
stable, and narrow wavelength band, which allows the Raman shifts 
to be calculated using the spectral distance from the excitation 
(Rayleigh scattered) band. They produce enough power to generate 
a significantly high Raman signal, but are limited by the intensity that 
leads to heating effects that may damage biological tissues. This may 
lead to time-consuming measurements due to the low probability to 
produce Raman photons. In addition, the light source wavelength 
may be absorbed by tissue chromophores (such as oxy and 
deoxyhaemoglobin, melanin, water, lipid), making 785 nm the choice 
of most of the systems for medical applications, as this wavelength 
is positioned in the “optical window”, the spectral region where 
biological tissue has highest light penetration. 
 Fibre optic probes are generally used for clinical Raman 
spectroscopy to optimize the light delivery and collection. These 
probes allow clinicians to access the region of interest anywhere in 
the patient body and can be designed for specific applications. This 
design involves optimum choice of optical fibre material, size, 
geometry, and surface modifications of the probe. Typically, silica 
(glass) fibre probes are used thanks to their relative low-cost and 
possibility to be sterilized. However, glass fibres have a strong Raman 
signal below 700 cm-1 28, which cannot be extracted from the 
collected measurement signal, in many cases. With regards to the 
size of the probe, a high collection signal and most of the design 
configurations are possible for probes with centimetres of diameter. 
On the other hand, if millimetre-sized probes are required, the 
options of design and intensity of captured signal may drop28. Major 
limitations for clinical translations rely on the high cost of the probes 
currently used in research (expensive assembly and optical filters) 
and artefacts of ambient light, which cannot be totally suppressed by 
currently used probes. Ambient light is a factor that must be taken 
into account, since creating a complete dark environment for clinical 
diagnostics or surgical guidance is not feasible. 
  
Advances in instrumentation 
 One of the main advances in instrumentation is the design of 
fibre optic probes for depth selectivity and fast acquisition time 
27,28,101–105. Depths from hundreds of micrometres until few 
centimetres can be reached by different fibre probe designs and 
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techniques (by changing the shape of the probe tip and the distance 
between the source and detector fibres) and adoption of the 
spatially offset Raman spectroscopy technique 106–115.  
 Advances in integration between instrumentation and data 
analysis reduced the acquisition times to less than one second and 
still had potential to give a precise diagnosis25,116–120. These systems 
are very sophisticated, but the equipment can be bulky and 
expensive, which hinders perspectives of clinical translation. 
Alternatively, the development of hand-held equipment may 
diversify the use of expensive instrumentation, since it is more 
ergonomic and portable 25,119,121. In this case, the instrumentation 
specifications tend to be high enough to give a precise diagnosis only 
if it contains expensive components that allow sufficient spectral 
resolution and acquisition time. For Raman imaging instrumentation, 
specifications may need to include spatial resolution and field-of-
view, which can add even more costs. Ideally, if the instrumentation 
needs to be used in a clinical routine, alternatives must be sought to 
allow clinics/hospitals to afford the equipment. Another relevant 
advance is fabricating low-cost disposable probes. Potentially cheap 
probes have been proposed by two research groups122,123. One of 
them used a disposable needle tip with fused silica fibers connected 
to a reusable probe with expensive components, while the other 
could be produced without expensive optical filters28 . 
 
Spectral pre-processing techniques 
 In the Raman spectroscopy context, data pre-processing consists 
in preparing the data to be analysed after spectra collection. It 
involves background subtraction for obtaining the desired Raman 
scattered signal, noise suppression, and enhancement of spectral 
differences based on shape, absolute intensity, and spectral position 
of Raman bands.  
Appropriate background subtraction must be performed in order 
to recover the true Raman spectrum, i.e., the Raman spectrum 
without interference of optical processes other than Raman 
scattering. Background subtraction includes techniques to eliminate 
the influence of fluorescence and other types of scattering 
processes, as mentioned in the previous sections. One of the few 
techniques developed to remove the influence of scattering in 
Raman spectra is called extended multiplicative scatter correction124, 
which was initially designed to analyse infrared spectra of powder 
mixtures. On the other hand, a wide range of methods is used for 
removing the influence of fluorescence. These methods include 
wavelet transformation, principal component analysis (PCA), 
penalized least squares, multistage smoothing, first- and second-
order differentiation, polynomial subtraction, and frequency filtering 
27,125–132. The latter two approaches are the most used ones. 
Polynomial subtraction consists in fitting a polynomial of sufficiently 
high order to describe the smooth fluorescence contribution without 
eliminate high frequency Raman signals and subsequent subtraction 
of this polynomial. Frequency-domain filtering consists in eliminating 
low frequency contributions in the signal after applying a fast Fourier 
transform. More advanced methods include principal component 
analysis, which removes the components of high spectral variance by 
assuming they are associated to the fluorescence background, and 
wavelet transformation, which relies on the shape of fluorescence 
spectrum underlying the Raman signal and on the choice of 
decomposition method27,132–134. 
 Noise suppression is mandatory in Raman spectra, as the real 
Raman contribution is weak and most of times hidden in a highly 
noisy signal. This suppression is especially useful to posterior 
biochemical characterization based on fitting of the Raman peaks, as 
it removes high-frequency features that might hinder the right 
determination of the peak position. It can be performed by applying 
filters such as Savitzky–Golay, Gaussian, median, and moving average 
window filters. The order of Savitzky–Golay filters is highly 
dependent on the system specifications (such as spectral resolution 
and efficiency of light collection) and measurement conditions (such 
as short integration time or dark current in the detector) that 
contribute to the signal noise. Gaussian filters rely on the system 
spectral resolution and are usually have the full width at half 
maximum set to half of this resolution 135–139. Advanced methods to 
supress high signal frequency components can use multivariate 
statistics or analysis such as PCA and genetic algorithms 139–143. Even 
though these methods remove noise extremely efficiently, they must 
be used carefully to not eliminate features of the true Raman 
spectrum, which has a significantly higher frequency than the 
background, but lower frequency than the random signal noise. An 
alternative to estimate the measurement noise is probing the 
different sources of noise in the used instrumentation. These sources 
may involve all the equipment components, thus making calibration 
essential to check for reliable noise suppression. In this calibration, a 
standard substance with known Raman spectrum should be 
measured to characterize the system response and checking whether 
the processed signal matches with the known (calibrated) Raman 
spectrum. 
 Enhancement of the spectral differences is highly used for tissue 
classification purposes after spectral pre-processing. It is typically 
performed by using difference spectra (subtraction from average 
spectra of the dataset) and normalizing the Raman spectrum in 
several ways. The most common types of normalization are 
normalizations to the area under the spectrum, maximum intensity 
of the spectrum, and mean scaling of the spectrum based on the 
intensity of the average spectrum in a particular Raman shift for a 
specific patient. For interpretation purposes, the first type assumes 
the same number of photons will be detected in each measurement, 
including the whole spectrum. On the other hand, the second and 
third types rely on a constant intensity of the strongest emission of 
the sample and on a constant emission in a certain wavelength for all 
the patients. 
  
Opportunities and challenges in data analysis 
 Analysis for clinical Raman spectroscopy can be divided in three 
main approaches: spectral feature extraction, tissue classification for 
direct diagnosis and biochemical characterization for interpretation 
of patient state. Feature extraction is based on the idea of finding 
new aspects that characterize hidden information or divisions in the 
patient group under study. As an example, one may be looking for 
grouping patients with benign or cancerous lesions. However, after 
analysing how patients are grouped upon comparison of certain 
features, one can see that patients could be separated by age 
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instead. This is performed by using unsupervised multivariate 
analysis methods, i.e., methods to analyse experimental spectra 
without prior knowledge of the studied subjects. These methods 
include cluster analysis and component analysis. Cluster analysis is 
based on grouping sets of subjects. The formed groups can have 
characteristics assigned to them (such as age, skin colour, and 
pathology) in order to check whether the groups are compatible with 
one of these characteristics. If each group obeys a trend in a given 
characteristic, a potential differentiation of subjects can be 
performed by using the measurement technique targeted in the 
study (Raman spectroscopy, in this case). Cluster analysis techniques 
comprise hierarchical cluster analysis, K-means, fuzzy C means, and 
Density-Based Spatial Clustering of Applications with Noise144–153. 
Component analysis is based on describing the subjects with new 
features. Examples of component analysis include PCA, linear 
discriminant analysis, and vertex component analysis. PCA is the 
most used method. It calculates features based on independent 
components (sum of weighted signals for each Raman shift) and 
order them from the highest to the lowest variance 141,143,153–157. This 
makes it suitable for decreasing the complexity of the spectra, i.e., 
analysing less Raman spectral features. Analysing thousands of 
values of Raman spectra may be complex and can lead to high 
computational costs, which means more time is required for data 
analysis. Therefore, PCA is used to extract the combinations of 
spectral features for quick data analysis while keeping the diagnosis 
performance158.  
 Tissue classification is widely used to create models to 
discriminate/differentiate among several types of biological tissues 
and predict what the category of a new measured tissue is. It is 
typically performed by using supervised multivariate analysis 
methods, i.e., methods that use to prior knowledge of the studied 
subjects to analyse the data (Raman spectra). Classification methods 
are incredibly powerful and can be used for precise diagnosis of 
many diseases. However, in order to achieve a reliable tissue 
classification, three requirements must be met. First, the sample size 
must be large enough to represent the whole group of studied 
objects, e.g., oral lesions. When the dataset used to generate the 
classification model is not sufficiently diverse and large, i.e., if it does 
not contain the typical heterogeneity of a clinical setting, the model 
may be too specific for the setting the study was conducted. This was 
demonstrated by a study that attributed acceptable diagnosis 
performance by models generated with 2 to 25 subject and good 
classification in studies involving 75 to 100 patients 159. Moreover, 
misclassification can lead patient severe consequences to the 
patients, thus making significant statistical difference a critical factor 
for diagnosis. Second, the model must be robust enough to achieve 
the diagnosis performance with every additional input data. In order 
to do this, the model should have as many internal and external 
validations as possible. For internal validation, part of the dataset is 
used as training set to build the model, while the other part (test set) 
is used to apply the model and test its accuracy. This can be done 
repeatedly until all parts of the dataset are used to calibrate the 
model and test it. Optimum model for each dataset is calculated by 
using the root-mean squared error of calibration and root-mean-
squared error of prediction. Several methods can be employed to 
estimate this accuracy such as k-fold cross-validation, permutation 
testing, and leave-one-out 153,160–162. After this, an external validation 
is required for testing the generated model with a second dataset, 
i.e., a larger dataset of newly measured Raman spectra (independent 
of the first dataset that was used to generate the model). The 
external validation is necessary because the first generated model 
may be biased, since it was optimized to classify data (biological 
tissues) in the first dataset. Third, the classification must be 
completely independent on the measurement conditions. This 
means that a standard of procedure must take place in order to make 
measurements more uniform and systematic across studies, in order 
to allow comparison among them and ultimately build a general 
model that is valid for all the set of instruments of a company, for 
example. This is important to calibrate Raman spectroscopy systems 
over time, as they can lose their diagnostic performance and may 
need maintenance. Tissue classification methods include support 
vector machines, linear discriminant analysis, quadratic discriminant 
analysis, partial least squares, logistic regression models, neural 
networks, decision trees, genetic algorithms, and general 
optimization techniques. 27,141,143,163–170 
 Finally, biochemical characterization is attractive for estimating 
biomolecules concentrations in tissues, which can provide metabolic 
information that may be useful in clinical monitoring cases, where 
many possibilities can happen such as processes of tissue healing and 
mineralization, treatment prognosis, and progress of bacterial or 
fungal infection. In these cases, classifying tissues may be hard due 
to many changes that can occur, which hinders the differentiation 
among stages. In this case, biochemical information may be useful 
for the clinicians to understand the patient situation by taking into 
consideration both this information and the patient history. 
Biochemical characterization is usually performed by deconvolving 
Raman spectra peaks into combinations of Gaussian curves. Each 
curve will be centred in the Raman shift correspondent to the 
described vibrational mode and the abundance certain biomolecules 
can be calculated by the area of the Gaussian curve, which indicates 
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Our team frequently makes clinical diagnosis in our units, and 
deal with histopathological results regarding biopsies previously 
performed in our offices. We take a recent clinical case as an 
example, to illustrate some possible applications of the technique 
and in what direction we can follow. 
 
  In figure 1, we show a clear example of a patient in whom optical 
biopsy procedures may assist both for diagnosis and for treatment. 
The patient has two distinct lesions, one in tongue and one in lip. The 
hypothetic clinical diagnosis of these lesions is leukoplakia, which is 
considered a potentially cancerous lesion. This makes the early-stage 
diagnosis highly recommended. 
Let us consider the lesion of the tongue (figure 1), which 
presented a nodule at the time of diagnosis. This nodule can 
consequently generate greater severity and is evidence that the 
lesion can progress towards an epidermoid carcinoma, as it was 
confirmed in the real case afterwards. In this context, traditional 
incisional biopsy is the chosen procedure for the final diagnosis, but 
a portable Raman spectroscopy device could help clinicians to 
identify features of each area, as shown in the figure 1. A "green" 
spectrum would represent a normal area, a "yellow" spectrum would 
represent an area doubtful, and a "red" spectrum would represent a 
potentially malignant/disease area. 
The problem addressed above refers to the use of the technique 
as diagnostic method. Once the oral lesion is diagnosed as cancer, 
the procedure that must be performed is the surgical removal with 
associated safety margin or not to radiotherapy. Then,  we can use 
again the Raman spectroscopy technique for the surgical procedure 
to guide us in the healthy or pathological safety margin, thus helping 
the clinician in his/her limitations (e.g. evaluations using naked eye) 
and providing a database for analysis of oral tissues at molecular 
level for fundamental applications. 
 Researchers have engaged into creating new groups and 
networks to accelerate the clinical implementation of vibrational 
spectroscopy techniques. Some of these groups include 
Raman4clinics and Clinical Infrared and Raman Spectroscopy 
Network (CLIRSPEC), in which some events are organized to 
stimulate the international and interdisciplinary community to 
collaborate and narrow discussions about challenges of clinical 
translation of Raman spectroscopy. 
 
What is next?  
In terms of instrumentation, Raman spectroscopy systems should 
include six main features: portability, low-cost, user-friendly 
interface, capable of providing accurate diagnosis, fast data 
acquisition and analysis, automated. Portability and low-cost 
development rely mostly on instrumentation. User-friendly interface 
and accurate diagnosis require both instrumentation and software 
aspects. Building an intuitive interface for clinicians involve the 
implementation of instrumentation features and software guidance 
based on a deep understanding about clinicians background and 
work environment. Improvements in instrumentation include 
buttons at the probe or foot pedals for taking measurements, while 
software advances may include possibility of modes for real-time 
signal update and for recording precise spectra (acquisition mode), 
real-time display of (easy interpretable) clinical data reports, and 
intuitive interface for changing equipment configurations. 
Automation and fast data acquisition and analysis are very 
dependent on software development. A big step in automation is 
integrating the data acquisition, data processing, and data analysis 
software, which should process all the information in real-time, 
including background removal, spectral smoothing, normalization, 
feature extraction, classification. For fast data acquisition and 
analysis, optimizing both steps with regards to computational costs 
is essential to provide a real-time data updates and generation of 
intuitive reports.  
 
Figure 1. Early oral squamous cell carcinoma of the tongue. Leukoplaquia in lip. Using 
the dots we would like to point out some Raman approaches. The spectrum itself could 
be translated into colours, as described in the text. 


































































































































Finally, with regards to the use of Raman spectroscopy as a daily 
clinical practice, obviously more studies and in vivo tests should be 
performed, but always with a focus that should have a real 
application; and it was our objective in the present work to show the 
community of spectroscopists what is really necessary, starting from 
a clinical point of view. Thus, we must expand our studies to: 1 - 
precise identification of potentially cancerous lesions (leukoplakia, 
erythroplakia, submucous fibrosis and actinic cheilitis), 2 - seek 
subtle changes in the healthy mucosa of patients at risk (e.g. 
smokers, or very exposed to solar radiation), changes in which we 
were not able to evidence in routine clinical examination, 3 - 
evaluation of infiltration or margin of lesions of squamous cell 
carcinoma, or even early stage epidermoid carcinoma, 4 – 
development of robust in vivo spectroscopy technique to identify 
other pathological complications that require early diagnosis 
(including cancer or not), such as autoimmune diseases, some fungal 
infections, among others. 
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